Taking advantage of a new compound named TD139, a highly potent, specific inhibitor of the galactoside binding pocket of Gal-3 a novel target therapy for IPF was proposed and a clinical trial process was started in 2014. Here, LGALS3 is linked to idiopathic pulmonary fibrosis.